Close Menu

lymphoma

NCI researchers performed a multi-platform study to elucidate the factors that can contribute to a patient's better-than-expected response to a drug.

In PNAS this week: genetic diversity and more among Nipah viruses, glycome expression study of the brain, and more.

The Swiss-American bioinformatics company touts its networks of multimodal data and numerous partnerships as it looks to support "data-driven medicine."

In PLOS this week: computational tool to uncover selection within populations, sequencing-based analysis of canine lymphoma, and more.

In PNAS this week: epigenetic study of Kaposi's sarcoma-associated herpesvirus, non-coding variant prioritization tool, and more.

Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.

The company will provide proprietary algorithms for analyzing omics and imaging data to define predictors of drug response and identify new biomarkers.

Transcriptomic and multi-omic data spanning more than 10,000 samples helped map "immunogenomic" interactions that may inform treatment outcomes and targets.

Investigators are planning to further validate specific applications, such as prediction of lung and lymphoma cancer subtypes, in independent sample sets.

The accelerated approval is based on results from two cohorts of a Phase II, single-arm trial in which EZH2-mutated patients had an overall response rate of 69 percent.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.